18% of the population. One Vision. Ongoing scheduled verification.
Saudi Arabia carries 18% diabetes prevalence — one of the highest in the world. The Ministry of Health has named lower-extremity amputation reduction a stated Vision 2030 priority. AimwellBio runs adversarial intelligence scoped to SFDA approvals, MOHAP procurement cycles, MOH formulary decisions, and the GCC + MENA manufacturing layer that supplies them. Wound care + diabetes are tracked together because the diabetic foot ulcer is where the two indications collide — and where Vision 2030 outcomes are won or lost.
▸ The Vision 2030 question worth surfacing
A national outcome target — amputation reduction inside an 18% diabetes prevalence base — cannot be defended on cross-border SaaS intelligence. The data residency, the signal velocity, the SFDA approval timing, and the procurement cycle all live inside the jurisdiction. The infrastructure should too.
Sovereign Discovery Assessment · scoped to your indication portfolio · 4–6 weeks · ends with deployment recommendation · USD/SAR by mandate.
18% of the KSA population. Among the highest globally. The number is the policy.
Diabetic foot ulcer is the operational endpoint where diabetes becomes wound care. MOH outcome targets fall here. Tracking the indication intersection is non-optional.
KSA + GCC manufacturing localization is no longer aspirational. Six anchored manufacturers under ongoing scheduled monitoring.
Saudi Pharmaceutical Industries & Medical Appliances Corp.; primary Saudi-domiciled manufacturer with active diabetes-formulary portfolio aligned to MOH procurement.
Saudi diabetes-care manufacturer headquartered in Tabuk; SFDA-aligned production for Vision 2030 sovereign-supply mandates.
Jeddah-based Saudi pharmaceutical group; diabetes and cardiometabolic portfolio expansion across MENA; Vision 2030-aligned localization.
Gulf Pharmaceutical Industries (UAE); first GCC manufacturer of recombinant insulin; sovereign-supply anchor for the Gulf diabetes population.
Jordan-headquartered; Levant + MENA + U.S. injectables footprint; broad diabetes-injectable manufacturing relevant to GCC sovereign procurement.
Cairo-based generic and branded manufacturer; substantial MENA diabetes-formulary footprint; cross-border supply to GCC sovereign markets.
AimwellBio cross-tags every diabetic foot ulcer signal as both wound-care AND diabetes. Currently tracking — cross-tagged signals.
The DFU is the clinical surface where MOH amputation-reduction targets are measured. Single-indication coverage misses it. Combined-vector coverage anchors it.
This page is generated from a live ingest pipeline (tools/scout-ingest) covering FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, with CMS LCD, USPTO Patent Center, and manufacturer pipeline pages calibrating. Updated —.
Confidence framework: source-backed > pattern-inferred > model-hypothesis > speculative. Sovereign vectors apply additional MOH / SFDA / MOHAP context layers as those data feeds come online.
Which 2030 outcome targets in your portfolio cannot be defended on cross-border SaaS intelligence?
Looking at Sovereign generally, not KSA-specific? See /sovereign →
Plus: KSA-scoped deployment includes SFDA approval timing, MOHAP procurement cycles, MOH formulary tracking, GCC + MENA manufacturing layer monitoring.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.